GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review
DOI:
https://doi.org/10.12775/QS.2025.41.60343Keywords
GLP-1 RA, semaglutide, type 2 diabetes, cardiovascular risk, macroalbuminuriaAbstract
Introduction: Type 2 diabetes is one of the greatest challenges of modern medicine. Its growing prevalence and numerous complications, especially cardiovascular ones, demand constant improvement of treatment strategies. Cardiovascular disease remains the leading cause of death in these patients, highlighting the importance of therapies that address both glycaemic control and cardiovascular risk.
Aim of the study: This paper discusses the effects of GLP-1 receptor agonists (GLP-1 RA) and analyses recent data on their impact on cardiovascular risk, renal function, and interaction with physical activity. Key clinical trials and practical applications in daily practice are also presented.
State of knowledge: GLP-1 RAs are well-established in the treatment of type 2 diabetes and obesity. They effectively lower glucose levels and reduce body weight while offering cardiovascular and nephroprotective benefits. Their role is particularly significant in patients with chronic kidney disease. Emerging data also suggest possible applications beyond diabetology, including neurology and cardiology.
Material and methods: A PubMed search was conducted using relevant keywords for studies available up to March 2025. Only English-language publications were included. After title and abstract screening, full texts of eligible articles were analysed.
Conclusions: GLP-1 RAs are a valuable part of therapy for patients with type 2 diabetes and obesity. They improve glycaemic control, support weight loss, and reduce cardiovascular and renal risk. Their safety profile allows for combination with other drugs. When used alongside physical activity, they can significantly enhance health outcomes and quality of life.
References
1. Alba Rojano Toimil, Andreea Ciudin GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes. J Clin Med 31;10(17):3955. Published 2021 Aug 31. doi: 10.3390/jcm10173955.
2. Fatima Ali Raza, Rafiya Altaf, Talha Bashir et al. Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review. Medicine (Baltimore). 1;103(44):e40364. Published 2024 Nov. doi: 10.1097/MD. c0000000000040364.
3. Ushna Gul, Thandar Aung, Mehwish Martin et al. A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure. Cureus 28;16(12):e76519. Published 2024 Dec. doi: 10.7759/cureus.76519.
4. Mario Simental-Mendia, Enrique Lindem-Torres, Adriana Sánchez-García et al. Effect of glucagon-like peptide-1 receptor agonists on renal function: A meta-analysis of randomised controlled trials. Br J Clin Pharmacol. 88(8):3566-3576. Published 2022 Aug. doi: 10.1111/bcp.15304 .
5. Marcel H A muskiet, Lennart Tonneijck, Mark M Smits et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 13(10):605-628. Published 2017 Oct. doi: 10.1038/nrneph.2017.123.
6. Daniel Yuan, Harman Sharma, Anirudh Krishnan et al. Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab 24(9):1869-1881. Published 2022 Sep. doi: 10.1111/dom.14776.
7. Daiji Kawanami, Yuichi Takashi GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms Front Pharmacol 30:11:967. Published 2020 Jun. doi: 10.3389/fphar.2020.00967.
8. Eulalia Valentina Greco, Giuseppina Russo, Annalisa Giagalia et al. GLP-1 Receptor Agonists and Kidney Protection. Medicina (Kaunas) 31;55(6):233. Published 2019 May 31. doi: 10.3390/medicina55060233.
9. Merlin C Thomas The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab 43 Suppl 1:2S20-2S27. Published 2017 April. doi: 10.1016/S1262-3636(17)30069-1.
10. Richard J Maclsaac, Philippa Trevella, Elif I Ekinci. Glucagon-like peptide-1 receptor agonists and kidney outcomes. J Diabetes. 16(10):e13609. Published 2024 Oct. doi: 10.1111/1753-0407.13609.
11. Meir Schechter, Cheli Melzer Cohen, Alisa Fishkin et al. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. Cardiovasc Diabetol. 27;22(1):126. Published 2023 May. doi: 10.1186/s12933-023-01829-0.
12. Ji Hee Yu, So Young Park, Da Young Lee et al. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions Kidney Res Clin Pract. 25;41(2):136-149. Published 2022 Mar. doi: 10.23876/j.krcp.22.001.
13. Daria Abasheva, Alberto Ortiz, Beatriz Fernandez-Fernandez. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity Clin Kidney J. 22;17(Suppl 2):19-35. Published 2024 Nov. doi: 10.1093/ckj/sfae296.
14. M Angelyn Bether, Rishi A Patel, Peter Merrill et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 6(2):105-113. Published 2018 Feb. doi: 10.1016/S2213-8587(17)30412-6.
15. Apostolos Tsapas, Thomas Karagiannis, Ioannis Avgerinos et al. GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Res Clin Pract. Jul:177:108921. Published 2021 Jul. doi: 10.1016/j.diabres.2021.108921.
16. Steven P Marso, Gilbers H Daniels, Kristine Brown-Frandsen et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 28;375(4):311-22. Published 2016 Jul. doi: 10.1056/NEJMoa1603827..
17. Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 13;394(10193):121-130. Published 2019 Jul. doi: 10.1016/S0140-6736(19)31149-3.
18. Xiaomei Chen, Xuge Zhang, Xiang Xiang et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 26;16(1):251. Published 2024 Oct. doi: 10.1186/s13098-024-01497-4.
19. Jie Zhang, Tong-Zhang Xian, Ming-Xiao Wu et al. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial. Cardiovasc Diabetol. 25;19(1):48. Published 2020 Apr. doi: 10.1186/s12933-020-01014-7.
20. Yukiko Hasegawa, Mika Hori, Tomoko Nakagami et al. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. J Clin Lipidol. Jan-Feb;12(1):62-69.e1. Published 2018 Jan-Feb. doi: 10.1016/j.jacl.2017.11.006.
21. Odai M Albahli, Saqib Ali, Fahad Alblaihi et al. The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Lipid Profile of Diabetic Patients Using Statins: A Retrospective Cohort Study in the Diabetic Center of King Salman Bin Abdulaziz Hospital, Saudi Arabia. Cureus. 27;16(7):e65521. Published 2024 Jul. doi: 10.7759/cureus.65521.
22. Antonino Tuttolomondo, Anna Cirrincione, Alessandra Casuccio et al. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial. Cardiovasc Diabetol. 4;20(1):1. Published 2021 Jan. doi: 10.1186/s12933-020-01183-5.
23. Yu Mi Kang, Chang Hee Jung. Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinol Metab (Seoul). 31(2):258-74. Published 2016 Jun. doi: 10.3803/EnM.2016.31.2.258.
24. Chithra Sreenivasan, Aneri Parikh, Aida j Francis et al. Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review. Cureus. 12;16(8):e66697. Published 2024 Aug. doi: 10.7759/cureus.66697.
25. Jing Qin, Li Song Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC Endocr Disord. 12;22(1):125. Published 2022 May. doi: 10.1186/s12902-022-01036-0.
26. Hidetaka Hamasaki. Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment? World J Diabetes. 15;9(8):138-140. Published 2018 Aug. doi: 10.4239/wjd.v9.i8.138.
27. P. Mensberg, S. Nyby, P. G. Jørgensen et al. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes Obes Metab. 19(2):172-180. Published 2017 Feb. doi: 10.1111/dom.12797.
28. Steven K. Malin. Understanding the Benefit of Combining GLP-1 Agonists With Exercise: Time Will Tell. J. Clin. Endocrinol Metab. 26;109(2):e860-e861. Published 2023 Jul. doi: 10.1210/clinem/dgad426.
29. Charlotte Janus, Dorte Vistisen, Hanan Amadid et al. Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men. Endocr. Connect. 8(12):1607-1617. published 2019 Dec. doi: 10.1530/EC-19-0408.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Łukasz Karaban, Tadeusz Kuźnieców, Monika Paszkowska, Klaudia Mularczyk, Michał Borawski, Aleksandra Ciuła, Anna Jakubiak, Joanna Miśkiewicz, Patrycja Znamirowska, Magdalena Kupis
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 82
Number of citations: 0
